Pharmacy and Therapeutics Committee Agenda for August 18, 2005
The Pharmacy and Therapeutics Committee will meet Thursday, August 18, 2005 from 10:30 a.m. to 3:00 p.m., in meeting room 3, Concourse, Empire State Plaza, Albany, New York.
Agenda Items: This meeting of the P &T Committee will be an informational session regarding the process for implementation of the Preferred Drug Program and related clinical issues.
1. Discussion: Overview of a Preferred Drug Program
Description: The Committee will be provided information about the overall goals and objective of the new program, the procedures required to implement the Preferred Drug Program, the role of the Committee, and the types of resources to be provided to the Committee during the decision-making process.
2. Discussion: The OHSU Drug Effectiveness Review Project
Description: The Committee will be provided a description of the process, products and support available from the Oregon drug Effectiveness Review program which will be available during the deliberations regarding the Preferred Drug Program.
3. Discussion: Implementation of the NYS's Preferred Drug Program:
Description: The Committee will be provided information regarding the types of categories generally used in other Medicaid and commercial preferred drug programs, and utilization patterns in the NYS Medicaid program.
10:30 - 10:40 Welcome and Introductions
10:40 - 11:40 Comments from interested parties*
11:40 - 12:30 Discussion: Overview of a PDP
12:30 - 1:00 Lunch Break
1:00 - 1:30 Discussion: The Oregon Drug Effectiveness Review
1:30 - 2:45 Discussion: Implementation of NYS PDP
2:45 - 3:00 Old Business
*Speakers must notify DOH at least 48 hrs in advance of their intent to speak at the committee meeting. To get on the agenda, you may call 518-486-3209 or e-mail firstname.lastname@example.org (please reference P&T Committee). Public comments are limited to the items on the agenda and must be brief. Written material may also be submitted to the Committee if received by DOH at least 48 hours in advance of the meeting. Written material should summarize key points and may not exceed two pages in length.